Vepafestinib

Overview

Vepafestinib (TAS0953/HM06) is a next-generation brain-penetrant, selective and orally active RET inhibitor with an IC 50 value of 0.33 nM. Vepafestinib inhibits the phosphorylation of RET and its downstream signaling pathways, thus blocking the growth and signal transduction of tumor cells and inducing cell cycle arrest and apoptosis . Vepafestinib can be used in the research of various RET-driven cancers, such as non-small cell lung cancer , thyroid cancer and other disease areas.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > RET | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-132846
• CAS No.: 2129515-96-2
• Molecular Formula: C26H30N6O3
• Molecular Weight: 474.55
• Purity: 98.61%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (2.11 mM); Clear solution
• Availability: In-stock

Source

Original product source